New stent aims to fix aortic aneurysms without open surgery

NCT ID NCT02777593

Ongoing Disease control Sponsor: W.L.Gore & Associates Source: ClinicalTrials.gov ↗

First seen Mar 16, 2026 · Last updated Jun 23, 2026 · Updated 12 times

Summary

This study is testing a new stent device called the GORE® TAG® Thoracic Branch Endoprosthesis to treat aneurysms or lesions in the aortic arch and upper part of the main artery from the heart. About 250 participants will receive the device to see if it is safe and effective. The goal is to repair the damaged area while avoiding serious complications like stroke or paralysis.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Baylor College of Medicine - Houston

Houston, Texas, 77030, United States
Cardiothoracic and Vascular Surgeons

Austin, Texas, 78756, United States
Cardiovascular Surgery Clinic

Memphis, Tennessee, 38120, United States
Carolinas HealthCare Systems

Charlotte, North Carolina, 28203, United States
Cedar-Sinai Medical Center

Los Angeles, California, 90048, United States
Cleveland Clinic

Cleveland, Ohio, 44195, United States
Cooper University Hospital

Camden, New Jersey, 08103, United States
Dartmouth-Hitchcock Medical Center

Lebanon, New Hampshire, 03766, United States
Duke University Medical Center

Durham, North Carolina, 27710, United States
Emory University

Atlanta, Georgia, 30322, United States
Hartford Hospital

Hartford, Connecticut, 06106, United States
Heart Hospital at Baylor Plano

Plano, Texas, 75093, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Houston Methodist Hospital

Houston, Texas, 77030, United States
Keck Medical Center of USC

Los Angeles, California, 90033, United States
Leland Stanford Junior University

Stanford, California, 94305-5407, United States
Massachusetts General Hospital

Boston, Massachusetts, 02114, United States
Mayo Clinic Rochester

Rochester, Minnesota, 55905, United States
MedStar Health Research Institute

Washington D.C., District of Columbia, 20010, United States
Memorial Hermann

Houston, Texas, 77030, United States
Northwestern University

Chicago, Illinois, 60611, United States
Oregon Health & Science University

Portland, Oregon, 97239, United States
Research Foundation SUNY Buffalo

Buffalo, New York, 14203, United States
Sentara Medical Group

Norfolk, Virginia, 23507, United States
St. Vincent Medical Group, Inc.

Indianapolis, Indiana, 46290, United States
Univeristy of South Florida

Tampa, Florida, 33606, United States
University of Florida - Gainesville

Gainesville, Florida, 32610, United States
University of Louisville Jewish Hospital

Louisville, Kentucky, 40202, United States
University of Michigan

Ann Arbor, Michigan, 48109, United States
University of Pittsburgh Medical Center

Pittsburgh, Pennsylvania, 15232, United States
University of Washington

Seattle, Washington, 98195, United States
University of Wisconsin System

Madison, Wisconsin, 53792, United States
University or Maryland Baltimore

Baltimore, Maryland, 21201, United States
Vanderbilt University Medical Center

Nashville, Tennessee, 37232, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

GORE® TAG® Thoracic Branch Endoprosthesis (a stent device placed inside the aorta to repair aneurysms or lesions)

What this could lead to

If successful, this device could offer a less invasive treatment option for people with aortic arch aneurysms, potentially reducing the need for open-heart surgery.

What could go wrong

This is an early-stage study with a composite endpoint, and results may not apply to all patients. Risks include stroke, paralysis, kidney failure, or device-related complications.

Conditions

The condition(s) this trial relates to.

aortic disorder thoracic aortic aneurysm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

AORTA; LESION AORTA; LESION AORTIC ANEURYSM, THORACIC